Technological advances and new tools may offer the best chance to help underdeveloped blood deserts in the short term.

The FDA has issued an alert about a potentially high-risk issue involving Abiomed’s Automated Impella Controller, which is used with the company’s blood pump systems. Abiomed, now part of ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial ...